Direct-to-Consumer Screening Companies

• Autores: Robert P. Oristaglio
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 313, Nº. 2, 2015, págs. 202-202
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • To the Editor The Viewpoint by Dr Wallace and colleagues1 appropriately framed the timely issue of early detection of disease in the medical community. This is a national debate, and there are strong, equally qualified, and conflicting opinions on all sides of this issue.

    Early detection of disease, which includes high-profile tests such as mammography and prostate-specific antigen level, is in the forefront of public awareness and should be a matter of public debate involving all participants in the medical community. Outcomes should not be determined by attacks on individual organizations, such as HealthFair, by Washington, DC–based policy groups such as Public Citizen. Outcomes should be determined by fair and proper public debate.